CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsHigh structural barrier to entry
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.20%
Annual Rate
INR 1.20Paid unknown
Payout Ratio
8.4%Sustainable
Last Ex-Dividend
Sep 19, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
101.40BINR1.06B · vs all stocks (USD)
Trailing P/E
40.91xvs Biotechnology peers
Revenue (TTM)
9.47BINR99.50M · vs all stocks (USD)
Profit Margin
26.16%vs Biotechnology peers
Beta
0.7730xvs all stocks
52-Week Change
-41.94%vs all stocks
Forward Annual Dividend Yield
0.20%vs all stocks
Market Capitalization
101.40BINR1.06B · vs all stocks (USD)
Enterprise Value
98.05BINR1.03B · vs all stocks (USD)
Trailing P/E
40.91xvs Biotechnology peers
Forward P/E
30.70xvs Biotechnology peers
PEG Ratio
-1.17xvs Biotechnology peers
Price to Sales (TTM)
10.70xvs Biotechnology peers
Price to Book (MRQ)
7.45xvs Biotechnology peers
Enterprise to Revenue
10.35xvs Biotechnology peers
Enterprise to EBITDA
33.34xvs Biotechnology peers
Gross Margin
56.45%vs Biotechnology peers
Profit Margin
26.16%vs Biotechnology peers
Operating Margin
27.62%vs Biotechnology peers
Return on Assets (TTM)
11.04%vs Biotechnology peers
Return on Equity (TTM)
19.88%vs Biotechnology peers
Revenue (TTM)
9.47BINR99.50M · vs all stocks (USD)
Revenue per Share (TTM)
54.63INRUpdated Jul 19, 2026Quarterly Revenue Growth
-31.10%vs Biotechnology peers
Gross Profit (TTM)
5.12BINR53.72M · vs all stocks (USD)
EBITDA (TTM)
4.36BINR45.76M · vs all stocks (USD)
Net Income (TTM)
2.48BINR26.03M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-41.60%vs Biotechnology peers
Operating Cash Flow (TTM)
3.34BINR35.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
795.49MINR8.36M · vs all stocks (USD)
Forward Annual Dividend Rate
1.20INRUpdated Jul 19, 2026Forward Annual Dividend Yield
0.20%vs all stocks
Trailing Annual Dividend Rate
1.20INRUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.20%vs all stocks
Payout Ratio
8.40%vs Biotechnology peers
Revenue
9.47BINRFY2026 · Mar 31, 2026Cost of Goods Sold
4.36BINRFY2026 · Mar 31, 2026Gross Profit
5.12BINRFY2026 · Mar 31, 2026Operating Income
2.70BINR28.37M · vs all stocks (USD)
Pre-tax Income
3.33BINRFY2026 · Mar 31, 2026Income Tax Expense
846.96MINRFY2026 · Mar 31, 2026Net Income
2.48BINRFY2026 · Mar 31, 2026EBIT
3.39BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
3.63BINRFY2026 · Mar 31, 2026Other Operating Expenses
1.44BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
62.39MINRFY2026 · Mar 31, 2026EPS (Basic)
14.29INRFY2026 · Mar 31, 2026EPS (Diluted)
14.29INRFY2026 · Mar 31, 2026Basic Shares Outstanding
173.42MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
173.42MSharesFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
4.64BINRFY2026 · Mar 31, 2026Free Cash Flow
2.45BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
608.57MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
3.33BINRFY2026 · Mar 31, 2026Other Non-cash Items
-26.51MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
279.58MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
1.07BINRFY2026 · Mar 31, 2026Capital Expenditures
-2.19BINRFY2026 · Mar 31, 2026Purchase of Investments
-4.09BINRFY2026 · Mar 31, 2026Sale of Investments
3.44BINRFY2026 · Mar 31, 2026Other Investing Activity
10.00KINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-2.84BINRFY2026 · Mar 31, 2026Common Dividends Paid
-208.18MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-208.18MINRFY2026 · Mar 31, 2026Shares Outstanding
173.47MSharesUpdated Jul 19, 2026Float Shares
33.18MSharesUpdated Jul 19, 2026% Held by Insiders
73.14%vs all stocks
% Held by Institutions
1.73%vs all stocks
Total Cash (MRQ)
3.76BINR39.45M · vs all stocks (USD)
Total Cash per Share (MRQ)
21.66INRUpdated Jul 19, 2026Total Debt (MRQ)
421.84MINR4.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0310xvs Biotechnology peers
Current Ratio (MRQ)
4.21xvs Biotechnology peers
Book Value per Share (MRQ)
78.41INRUpdated Jul 19, 2026Total Assets
16.41BINR172.37M · vs all stocks (USD)
Total Current Assets
9.57BINRFY2026 · Mar 31, 2026Total Liabilities
2.81BINRFY2026 · Mar 31, 2026Total Non-current Assets
6.84BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
537.90MINRFY2026 · Mar 31, 2026Total Current Liabilities
2.27BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
608.57MINRFY2026 · Mar 31, 2026Other Short-term Investments
3.27BINRFY2026 · Mar 31, 2026Accounts Receivable
3.39BINRFY2026 · Mar 31, 2026Inventory
1.87BINRFY2026 · Mar 31, 2026Accounts Payable
569.20MINRFY2026 · Mar 31, 2026Short-term Debt
46.04MINRFY2026 · Mar 31, 2026Other Current Liabilities
19.95MINRFY2026 · Mar 31, 2026Long-term Debt
375.80MINRFY2026 · Mar 31, 2026Common Stock (Book)
346.93MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
13.60BINR142.83M · vs all stocks (USD)
52-Week Low
325.00INRUpdated Jul 19, 202652-Week High
1.03KINRUpdated Jul 19, 202652-Week Change
-41.94%vs all stocks
Beta
0.7730xvs all stocks
50-Day MA
502.52INRUpdated Jul 19, 2026200-Day MA
486.20INRUpdated Jul 19, 2026Avg 10-Day Volume
1.28MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.01MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
14.29INRUpdated Jul 19, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
How is this stock valued?
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Changchun BCHT Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CK Life Sciences Int'l.,
Tier 1ProductionApproval-Gated PipelineFlowInterface
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedCash Backing With OCF Coverage And Cash Near Total Debt
Thyrocare Technologies Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedCash Backing With OCF Coverage And Cash Near Total Debt
Zozo, Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingCash Backing With OCF Coverage And Cash Near Total Debt